DK1868998T3 - Nye heterocykliske forbindelser, fremstilling deraf og anvendelse deraf som medikamenter, især som anti-alzheimer-midler - Google Patents

Nye heterocykliske forbindelser, fremstilling deraf og anvendelse deraf som medikamenter, især som anti-alzheimer-midler Download PDF

Info

Publication number
DK1868998T3
DK1868998T3 DK06742673.4T DK06742673T DK1868998T3 DK 1868998 T3 DK1868998 T3 DK 1868998T3 DK 06742673 T DK06742673 T DK 06742673T DK 1868998 T3 DK1868998 T3 DK 1868998T3
Authority
DK
Denmark
Prior art keywords
methyl
dimethylcarbamate
stage
dihydroquinoline
carboxylate
Prior art date
Application number
DK06742673.4T
Other languages
English (en)
Inventor
Pierre Bohn
Vincent Levacher
Fur Nicolas Le
Francis Marsais
Original Assignee
Vfp Therapies
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP05290914A external-priority patent/EP1731507A1/en
Application filed by Vfp Therapies filed Critical Vfp Therapies
Application granted granted Critical
Publication of DK1868998T3 publication Critical patent/DK1868998T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/92—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with a hetero atom directly attached to the ring nitrogen atom
    • C07D211/96—Sulfur atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/80—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D211/84—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen directly attached to ring carbon atoms
    • C07D211/86—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/80—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D211/84—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen directly attached to ring carbon atoms
    • C07D211/90—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C07D215/24—Oxygen atoms attached in position 8
    • C07D215/26—Alcohols; Ethers thereof
    • C07D215/32—Esters
    • C07D215/34—Carbamates
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/36—Sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C07D215/54—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
    • C07D217/24—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Neurosurgery (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Claims (12)

1. Ethyl 1 -methyl-7-(A/,A/-dimethylcarbamat)-1,4-dihydroquinolin-3-carboxylat;
1. Ethyl 1 -methyl-7-(A/,A/-dimethylcarbamat)-1,4-dihydroquinolin-3-carboxylat;
1. Forbindelse med formel G3a eller G3+
hvor Ri er (C1-C4) alkyl, R2 er H, (C1-C4) alkyl, R3 er en elektrontrækkende gruppe udvalgt fra gruppen omfattende COOR, COSR, CONRR', CN, COR, CF3, SOR, S02R, SONRR', S02NRR', N02, halogen, heteroaryl, hvor R, R' er en gruppe H, alkyl, cycloalkyl, arylalkyl, heteroarylalkyl, hydroxyalkyl, alkoxyalkyl, aryloxyalkyl, alkylaminoalkyl, aminoalkyl, heteroaryloxyalkyl, ha-logenoalkyl, thioalkyl, thioalkoxyalkyl, aryl, alkylaryl, hydroxyaryl, alkoxyaryl, aryloxyaryl, aminoaryl, alkylaminoaryl, halogenoaryl, heteroaryl, alkylheteroa-ryl, alkoxyheteroaryl, aminoheteroaryl, alkylaminoheteroaryl, halogenohe-teroaryl, eller R og R' sammen med det nitrogenatom, hvortil de er knyttet, danner en hete-rocyklisk ring med mindst 3 led, fortrinsvis en 5- eller 6-leddet heterocyklisk ring, eventuelt substitueret med en eller flere grupper, der er som defineret for R2, eller R og R' sammen med det nitrogenatom, hvortil de er knyttet, danner et kondenseret polyheterocyklisk system fortrinsvis tetrahydroisoquinolin, indolin, isoindolin, eventuelt substitueret med en eller flere grupper, der er som defineret for R2, R4 og R6 er Η, Zi er OCONR7R8, R7 og Rs, som er identiske eller forskellige, er hydrogen, (C1-C8) alkyl, aryl, heteroaryl, (C1-C8) alkylaryl, phenyl, cyclop-ropyl, (CH2)n-COOH; og hvor n ligger mellem 1 og 6; eller et farmaceutisk salt eller en stereoisomer deraf.
2. Ethyl 1 -methyl-5-(/V,/V-dimethylcarbamat)-1,4-dihydroquinolin-3-carboxylat;
67. Methyl 1 -methyl-5-(N,N-dimethylcarbamat)-1,4-dihydroquinolin-3-carboxylat; 68. 1 -Methyl-3-(N-methylcarboxamido)-5-(N,N-dimethylcarbamat)-1,4-dihydroquinolin; 69. [3-(N,N-methylcarboxamido)-5-(N,N-dimethylcarbamat)]-1,4-dihydroquinolin; 74. [Methyl 1-methyl-8-(N,N-dimethylcarbamat)-3-carboxylat]-1,4- dihydroquinolin eller 1,2-dihydroquinolin;
76. Methyl 1 -methyl-5-(N-ethylcarbamat)-1,4-dihydroquinolin-3-carboxylat; 77. [Ethyl 1-methyl-8-(N,N-dimethylcarbamat)-3-carboxylat]-1,4- dihydroquinolin; 78. 1 -Methyl-3-(N-propylcarboxamido)-7-(N,N-dimethylcarbamat)-1,4- dihydroquinolin eller deres tilsvarende ammoniumform deraf.
2. Ethyl 1 -methyl-5-(A/,A/-dimethylcarbamat)-1,4-dihydroquinolin-3-carboxylat;
2. Forbindelse med formel G3 eller G3+ som defineret i krav 1:
3. Forbindelse med formel G3 eller G3+ ifølge krav 2:
3. Ethyl 1 -methyl-5,7-di(A/,A/-dimethylcarbamat)-1,4-dihydroquinolin-3- carboxylat;
4. Forbindelse med formel G3 eller G3+ ifølge krav 2 eller 3:
67. Methyl 1 -methyl-5-(N,N-dimethylcarbamat)-1,4-dihydroquinolin-3-carboxylat; 68. 1 -Methyl-3-(N-methylcarboxamido)-5-(N,N-dimethylcarbamat)-1,4-dihydroquinolin eller deres tilsvarende ammoniumform deraf.
4. Ethyl 1 -methyl-5,8-di(A/,A/-dimethylcarbamat)-1,4-dihyd roquinolin-3- carboxylat;
5. Inklusionskompleks af en forbindelse som defineret i et hvilket som helst af kravene 1 til 4 med en beta-cyclodextrin.
5. Ethyl 1 -methyl-5-(N,N-dimethylthiocarbamat)-1,4-dihydro-5-0-quinolin-3-carboxylat;
6. Inklusionskompleks ifølge krav 5 med en hydroxypropyl-betacyclodextrin.
6. Ethyl 1 -methyl-5-(A/,A/-dimethylthiocarbamat)-1,4-dihydro-5-S-quinolin-3-carboxylat; 7. 1 -Methyl-5-(A/,A/-dimethylcarbamat)-3-(A/,A/-diethylcarboxamido)-1,4-dihydroquinolin; 8. 1-Methyl-7-(A/,A/-dimethylcarbamat)-3-(4,5-dihydro-4,4-dimethyl-2-oxazolyl)-1,4-dihydroquinolin; 9. 1 -Methyl-5-(A/,A/-dimethylcarbamat)-3-trifluoromethyl-1,4-dihydroquinolin; 10. (+/-)-1 -Methyl-3-(4-methylphenylsulfinyl)-5-(A/,A/-dimethylcarbamat)-1,4-quinolin; 11. 1 -Methyl-3-(4-methylphenylsulfonyl)-5-(A/,A/-dimethylcarbamat)-1,4-dihydroquinolin; 12. 1 -Methyl-5-(A/,A/-dimethylcarbamat)-3-(A/-phenylsulfomanid)-1,4-dihydroquinolin; 13. 1 -Methyl-6,7-di(A/,A/-dimethylcarbamat)-3-nitro-1,4-dihydroquinolin;
14. Ethyl 1-methyl-2-phenyl-6,7-di(A/,A/-dimethylcarbamat)-1,4- dihydroquinolin-3-carboxylat;
15. Ethyl 1,2,4-trimethyl-7-(A/,A/-dimethylcarbamat)-1,4-dihydroquinolin-3-carboxylat; 16. ; 17. - 18. - 19. - 20. -21. -22. - 23. - 24. - 25. - 26. -27. - 28. - 29. - 30. - 31. - 32. - 33. - 34. - 35. - 36. - 37. - 38. - 39. - 40. - 41. - 42. - 43. - 44. - 45. - 46. - 47. - 48. - 49. -59. - 51. - 52. - 53. - 54. - 55. - 56. - 57. - 58. - 59. - 69. -61. -62. -63. - 64. - 65. - 66. -
67. Methyl 1-methyl-5-(A/,A/-dimethylcarbamat)-1,4-dihydroquinolin-3-carboxylat; 68. 1 -Methyl-3-(N-methylcarboxamido)-5-(/V,/V-dimethylcarbamat)-1,4-dihydroquinolin; 69. [3-(N,N-methylcarboxamido)-5-(N,N-dimethylcarbamat)]-1,4-dihydroquinolin; 70. 71. - 72. - 73. - 74. [Methyl 1-methyl-8-(N,N-dimethylcarbamat)-3-carboxylat]-1,4- dihydroquinolin; 75. ;
76. Methyl 1 -methyl-5-(N-ethylcarbamat)-1,4-dihydroquinolin-3-carboxylat; 77. [Ethyl 1-methyl-8-(A/,A/-dimethylcarbamat)-3-carboxylat]-1,4- dihydroquinolin; 78. 1 -Methyl-3-(N-propylcarboxamido)-7-(N,N-dimethylcarbamat)-1,4-dihydroquinolin; eller deres tilsvarende ammoniumform deraf.
7. Farmaceutisk sammensætning omfattende mindst en forbindelse ifølge et hvilket som helst af kravene 1 til 6 og en farmakologisk acceptabel bærer.
8. Farmaceutisk sammensætning ifølge krav 7 til anvendelse ved behandling af neurodegenerative sygdomme, fortrinsvis Alzheimers sygdom hos et humant eller andet dyreindivid.
9. Forbindelse med formel G'3;
G’3 hvor R2 R3 R4 R6, Z-i er som defineret i krav 1.
10. Fremgangsmåde til fremstilling af en forbindelse med formel G3a, ifølge krav 1, som omfatter trinnet med reduktion af en forbindelse med formel (G3+) W\ hvor W er en fraspaltelig enhed udvalgt blandt halogen, O-triflat, carbo-xylat, sulfat, tosylat, mesylat, i nærvær af et reduktionsmiddel.
11. Fremgangsmåde til fremstilling af en forbindelse med formel (G3+)W som defineret i krav 1, som omfatter et trin med kvaternisering af nitrogenatomet af en forbindelse med formed G'3 som defineret i krav 9, ved hjælp af et alky- leringsmiddel RrW, idet Ri er (C1-C4) alkyl; idet W er en fraspaltelig enhed som defineret i krav 10.
12. Fremgangsmåde til fremstilling af en forbindelse med formel G'3 ifølge krav 9, som omfatter et trin med carbamylering af en forbindelse med følgende formel E3
E3 hvor P er OH; med et middel med formel W- CO-NR7R8 hvor W er en fraspaltelig enhed udvalgt blandt halogen, O-triflat, sulfat, to-sylat, mesylat, og R2 R3 R4, R7, Rs har den samme betydning som defineret i krav 1.
DK06742673.4T 2005-04-01 2006-03-29 Nye heterocykliske forbindelser, fremstilling deraf og anvendelse deraf som medikamenter, især som anti-alzheimer-midler DK1868998T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP05290719 2005-04-01
EP05290914A EP1731507A1 (en) 2005-04-26 2005-04-26 New heterocyclic compounds, their preparation and their use as medicaments, in particular as anti-alzheimer agents
PCT/EP2006/003787 WO2006103120A2 (en) 2005-04-01 2006-03-29 New heterocyclic compounds, their preparation and their use as medicaments, in particular as anti-alzheimer agents

Publications (1)

Publication Number Publication Date
DK1868998T3 true DK1868998T3 (da) 2016-08-29

Family

ID=36590178

Family Applications (1)

Application Number Title Priority Date Filing Date
DK06742673.4T DK1868998T3 (da) 2005-04-01 2006-03-29 Nye heterocykliske forbindelser, fremstilling deraf og anvendelse deraf som medikamenter, især som anti-alzheimer-midler

Country Status (9)

Country Link
US (1) US7977354B2 (da)
EP (1) EP1868998B1 (da)
AU (1) AU2006228683B2 (da)
CA (1) CA2603345C (da)
DK (1) DK1868998T3 (da)
IL (1) IL186233A (da)
NZ (1) NZ561953A (da)
SG (1) SG161217A1 (da)
WO (1) WO2006103120A2 (da)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102007042754A1 (de) 2007-09-07 2009-03-12 Bayer Healthcare Ag Substituierte 6-Phenylnikotinsäuren und ihre Verwendung
AR072899A1 (es) 2008-08-07 2010-09-29 Merck Sharp & Dohme Derivados de terpiridina-carboxamida antagonistas de receptores de orexina, composiciones farmaceuticas que los contienen y uso de los mismos en el tratamiento del insomnio y la obesidad.
CA2741644C (en) * 2008-10-30 2013-05-07 Merck Sharp & Dohme Corp. Isonicotinamide orexin receptor antagonists
US9290453B2 (en) 2010-12-23 2016-03-22 Merck Sharp & Dohme Corp. Quinolines and aza-quinolines as CRTH2 receptor modulators
CA2818597A1 (en) 2010-12-23 2012-06-28 Merck Sharp & Dohme Corp. Quinoxalines and aza-quinoxalines as crth2 receptor modulators
US8946261B2 (en) 2011-02-14 2015-02-03 Council Of Scientific & Industrial Research Substituted 1, 2, 3, 4-tetrahydroquinolin-7-yl carbamates as acetylcholinesterase inhibitors for treatment of Alzheimer's disease
WO2014113495A1 (en) 2013-01-15 2014-07-24 The Trustees Of Columbia University In The City Of New York Activation or reactivation of ache
EP2759536A1 (en) 2013-01-25 2014-07-30 INSA (Institut National des Sciences Appliquees) de Rouen Oxidisable pyridine derivatives, their preparation and use as anti-Alzheimer agents
AU2014216178B2 (en) 2013-02-15 2018-06-28 KALA BIO, Inc. Therapeutic compounds and uses thereof
BR112015020139A2 (pt) 2013-02-20 2017-07-18 Kala Pharmaceuticals Inc compostos terapêuticos e usos dos mesmos
US9688688B2 (en) 2013-02-20 2017-06-27 Kala Pharmaceuticals, Inc. Crystalline forms of 4-((4-((4-fluoro-2-methyl-1H-indol-5-yl)oxy)-6-methoxyquinazolin-7-yl)oxy)-1-(2-oxa-7-azaspiro[3.5]nonan-7-yl)butan-1-one and uses thereof
US9890173B2 (en) 2013-11-01 2018-02-13 Kala Pharmaceuticals, Inc. Crystalline forms of therapeutic compounds and uses thereof
KR20160099084A (ko) 2013-11-01 2016-08-19 칼라 파마슈티컬스, 인크. 치료 화합물의 결정질 형태 및 그의 용도
CN105622501B (zh) * 2016-03-30 2019-02-19 皖南医学院 N-芳基-3-碘代喹啉衍生物及其制备方法
AU2017324716B2 (en) 2016-09-08 2020-08-13 KALA BIO, Inc. Crystalline forms of therapeutic compounds and uses thereof
CN109688818A (zh) 2016-09-08 2019-04-26 卡拉制药公司 治疗化合物的晶型及其用途
EP3509422A4 (en) 2016-09-08 2020-05-20 Kala Pharmaceuticals, Inc. CRYSTALLINE FORMS OF THERAPEUTIC COMPOUNDS AND USES THEREOF
BR112019009529A2 (pt) 2016-11-11 2019-07-30 Bayer Animal Health Gmbh novos derivados de quinolina
AU2020365108A1 (en) 2019-10-18 2022-04-21 Atengen, Inc. 3-phenylsulphonyl-quinoline derivatives as agents for treating pathogenic blood vessels disorders

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IE892088L (en) 1988-07-12 1990-01-12 William Henry Deryk Morris Quinoline derivatives, their production and use
US5714615A (en) * 1994-02-08 1998-02-03 Georgia Tech Research Corporation Pyridinium compounds
IL115113A (en) 1995-08-31 2002-11-10 Israel State 3-carbamoyloxy pyridinium derivatives and pharmaceutical compositions containing them
CN1951939A (zh) * 2001-05-24 2007-04-25 伊莱利利公司 作为药物的新的吡唑衍生物

Also Published As

Publication number Publication date
AU2006228683B2 (en) 2012-02-02
US20090062279A1 (en) 2009-03-05
WO2006103120A3 (en) 2007-02-15
IL186233A (en) 2012-07-31
EP1868998A2 (en) 2007-12-26
CA2603345C (en) 2017-05-02
IL186233A0 (en) 2008-01-20
US7977354B2 (en) 2011-07-12
NZ561953A (en) 2011-11-25
WO2006103120A2 (en) 2006-10-05
CA2603345A1 (en) 2006-10-05
EP1868998B1 (en) 2016-05-25
SG161217A1 (en) 2010-05-27
AU2006228683A1 (en) 2006-10-05

Similar Documents

Publication Publication Date Title
DK1868998T3 (da) Nye heterocykliske forbindelser, fremstilling deraf og anvendelse deraf som medikamenter, især som anti-alzheimer-midler
EP1202987B1 (en) Quinoline derivatives and their use as antibacterial agents
KR100929942B1 (ko) Ｍｇｌｕｒ５ 길항제로서 피리딘-2-카복사미드 유도체
JP2000504336A (ja) 薬学製剤として有用なヘテロ環式化合物
EP2463276B1 (en) Nitrogenous-ring acylguanidine derivative
CA2465344A1 (en) Therapeutic quinolone compounds with 5-ht-antagonistic properties
CA2465350A1 (en) Therapeutic quinoline compounds with 5-ht-antagonistic properties
JP2002515486A (ja) 掻痒性皮膚病の治療用の新規４−フェニルピペリジン
JPS59219260A (ja) 新規なナフタレン−およびアザナフタレン−カルボキサミド誘導体、それを含有する製薬学的組成物、並びにそれらの製造法
BG60538B2 (bg) Нови //бис(арил)метилен/-1-пиперидинил/-алкил-пиримидинони
JP2889056B2 (ja) メタノアントラセン化合物、該化合物を含有する精神病治療用医薬調剤および上記化合物の製造方法ならびに中間体
AU2021410119A1 (en) Tetrahydroquinoline derivative and medicinal use thereof
JP5448448B2 (ja) 同位体置換されたプロトンポンプインヒビター
US5681840A (en) Tricyclic antipsychotic compounds
Muzalevskiy et al. Synthesis of 2-trifluoromethylated quinolines from CF 3-alkenes
CA2072520A1 (en) 2-(1-piperidyl) ethanol derivatives, their preparation and their therapeutic application
HU182562B (en) Process for preparing new 4-amino-2-piperidino-quinazoline derivatives
JP3523174B2 (ja) キノリン−４−イル誘導体
JPS62198680A (ja) １，６−ナフチリジン誘導体、その製造方法およびそれを含有する薬剤組成物
WO2006093253A1 (ja) キノリルアルキルチオ基を有する新規環式化合物
JPS63130581A (ja) ２‐置換‐１，４‐ジヒドロピリジン類の製造方法
EP1731507A1 (en) New heterocyclic compounds, their preparation and their use as medicaments, in particular as anti-alzheimer agents
WO2009087649A1 (en) Renin inhibitors
US7601737B2 (en) Isotopically substituted proton pump inhibitors
EP0265947B1 (en) Dihydropyridine derivatives, process for their preparation, pharmaceutical composition and use